Licartin, an antibody against HAb18G/CD147, has been approved to treat primary hepatocellular carcinoma and to prevent tumor recurrence after liver transplantation or radiofrequency ablation in China [16, 17]. Here, BSG is linked to hepatocellular carcinoma.